HPC6
MCID: PRS136
MIFTS: 41

Prostate Cancer, Hereditary, 6 (HPC6)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostate Cancer, Hereditary, 6

MalaCards integrated aliases for Prostate Cancer, Hereditary, 6:

Name: Prostate Cancer, Hereditary, 6 57 12 71
Prostate Cancer, Susceptibility to 57
Prostate Cancer 57
Hpc6 57

Classifications:



External Ids:

OMIM® 57 609558
MedGen 40 C1836005
UMLS 71 C1836005

Summaries for Prostate Cancer, Hereditary, 6

MalaCards based summary: Prostate Cancer, Hereditary, 6, also known as prostate cancer, susceptibility to, is related to prostate cancer and prostate cancer, hereditary, 8. An important gene associated with Prostate Cancer, Hereditary, 6 is HPC6 (Prostate Cancer, Susceptibility To). The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and bone.

More information from OMIM: 609558

Related Diseases for Prostate Cancer, Hereditary, 6

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1612)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 12.4
2 prostate cancer, hereditary, 8 12.1
3 prostate cancer, hereditary, 1 11.7
4 prostate cancer, hereditary, 2 11.7
5 prostate cancer, hereditary, 4 11.7
6 prostate cancer, hereditary, 13 11.6
7 prostate cancer, hereditary, 12 11.6
8 prostate cancer, hereditary, 11 11.6
9 prostate cancer, hereditary, 7 11.5
10 pachyonychia congenita 3 11.5
11 prostate disease 11.5
12 prostate cancer, hereditary, 3 11.5
13 prostate cancer, hereditary, 9 11.5
14 prostate cancer/brain cancer susceptibility 11.5
15 prostate cancer, hereditary, x-linked 1 11.4
16 prostatic hyperplasia, benign 11.4
17 prostate cancer, hereditary, 10 11.4
18 prostate cancer, hereditary, 15 11.3
19 prostate cancer, hereditary, 14 11.3
20 prostate cancer, hereditary, x-linked 2 11.3
21 prostate cancer, hereditary, 5 11.3
22 suppression of tumorigenicity 12 11.2
23 breast cancer 11.2
24 impotence 11.2
25 diethylstilbestrol syndrome 11.2
26 radiation proctitis 11.2
27 alopecia, androgenetic, 1 11.1
28 tatton-brown-rahman syndrome 11.1
29 prostate cancer aggressiveness quantitative trait locus on chromosome 19 11.1
30 breast-ovarian cancer, familial 1 11.1
31 adenocarcinoma 11.1
32 prostate sarcoma 11.0
33 diffuse gastric and lobular breast cancer syndrome 11.0
34 prostate lymphoma 11.0
35 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 11.0
36 prostate malignant phyllodes tumor 11.0
37 rhabdomyosarcoma 2 11.0
38 severe combined immunodeficiency 11.0
39 neutropenia 11.0
40 prostatitis 11.0
41 factor vii deficiency 11.0
42 rickets 11.0
43 ceroid lipofuscinosis, neuronal, 5 10.9
44 pure red-cell aplasia 10.9
45 bladder cancer 10.9
46 bone disease 10.9
47 49, xxxxy syndrome 10.9
48 neurodegeneration with brain iron accumulation 2a 10.9
49 proctitis 10.9
50 47 xxx syndrome 10.8

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 6:



Diseases related to Prostate Cancer, Hereditary, 6

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 6

Clinical features from OMIM®:

609558 (Updated 08-Dec-2022)

Drugs & Therapeutics for Prostate Cancer, Hereditary, 6

Drugs for Prostate Cancer, Hereditary, 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 833)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523 135413547
4
Zoledronic acid Approved Phase 4 118072-93-8 68740
5
Finasteride Approved Phase 4 98319-26-7 57363
6
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
7
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
8
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Lenograstim Approved, Investigational Phase 4 135968-09-1
12
Ranitidine Approved, Withdrawn Phase 4 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
13
Nitric Oxide Approved Phase 4 10102-43-9 145068
14
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
17
Granisetron Approved, Investigational Phase 4 109889-09-0 3510 5284566
18
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
21
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
22
Desflurane Approved Phase 4 57041-67-5 42113
23
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
24
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
25
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
26
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Icodextrin Approved, Investigational Phase 4 337376-15-5
29
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
30
Fosfomycin Approved Phase 4 23155-02-4 446987
31
Denosumab Approved Phase 4 615258-40-7
32
Pamidronic acid Approved Phase 4 40391-99-9 4674
33
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
34
Ibuprofen Approved Phase 4 15687-27-1 3672
35
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
36
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
37
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
38
Lactitol Approved, Investigational Phase 4 585-86-4 157355
39
Cabergoline Approved Phase 4 81409-90-7 54746
40
Abarelix Approved, Investigational, Withdrawn Phase 4 183552-38-7 21879626 16131215
41
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
42
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
43
Amdinocillin Investigational, Withdrawn Phase 4 32887-01-7 36273
44 Phosphodiesterase Inhibitors Phase 4
45 Gastrointestinal Agents Phase 4
46 Diphosphonates Phase 4
47 Anesthetics Phase 4
48 5-alpha Reductase Inhibitors Phase 4
49 Folic Acid Antagonists Phase 4
50 Anti-Ulcer Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 5255)
# Name Status NCT ID Phase Drugs
1 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
2 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
3 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
4 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
5 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
6 Prospective Evaluation of Truebeam STX Stereotactic Body Radiosurgery for Low and Intermediate Risk Prostate Cancer Unknown status NCT01581749 Phase 4
7 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
8 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
9 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
10 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
11 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
12 A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 Enzalutamide
13 The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients Completed NCT04776889 Phase 4 Rosuvastatin 20mg
14 A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study Completed NCT02721433 Phase 4 Pamidronate;Denosumab;Zoledronate
15 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
16 A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CONTINUED ENZALUTAMIDE TREATMENT BEYOND PROGRESSION IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Completed NCT01995513 Phase 4 Enzalutamide;Abiraterone;Placebo for Enzalutamide;Prednisone
17 A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) Completed NCT03035032 Phase 4 Leuprolide
18 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
19 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
20 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
21 An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer Completed NCT02726009 Phase 4 Degarelix
22 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
23 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
24 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
25 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
26 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
27 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
28 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
29 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
30 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
31 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
32 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
33 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
34 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
35 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
36 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
37 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
38 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
39 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
40 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
41 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
42 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
43 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
44 PRospective, Multicenter Study to Evaluate Safety and Efficacy of Switching Treatments of Prostate Cancer Patients, Initially on Use of Monthly or Quarterly Goserelin Acetate (Zoladex®), to Semiannually Leuprorelin Acetate (Eligard®) Completed NCT05304169 Phase 4 Leuprorelin Acetate (Eligard® 45 mg).
45 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
46 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
47 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
48 A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT) Completed NCT02918968 Phase 4 Enzalutamide;Flutamide
49 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg
50 Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate

Search NIH Clinical Center for Prostate Cancer, Hereditary, 6

Genetic Tests for Prostate Cancer, Hereditary, 6

Anatomical Context for Prostate Cancer, Hereditary, 6

Organs/tissues related to Prostate Cancer, Hereditary, 6:

MalaCards : Prostate, Lymph Node, Bone, Breast, Bone Marrow, T Cells, Lung

Publications for Prostate Cancer, Hereditary, 6

Articles related to Prostate Cancer, Hereditary, 6:

(show top 50) (show all 30009)
# Title Authors PMID Year
1
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. 62 57
17478474 2007
2
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 62 57
15988677 2005
3
Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. 57
20631155 2010
4
Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. 57
18066601 2008
5
Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. 57
17047086 2006
6
Prostate cancer aggressiveness and financial toxicity among prostate cancer patients. 62
36063402 2023
7
Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men. 62
35900615 2022
8
Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. 62
36453265 2022
9
Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36: Let's Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice. 62
36405303 2022
10
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. 62
35134266 2022
11
Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer? 62
36153247 2022
12
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. 62
32543166 2022
13
Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer. 62
35171081 2022
14
Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. 62
35899494 2022
15
Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. 62
35181473 2022
16
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). 62
35934601 2022
17
Microbiota and prostate cancer. 62
34536504 2022
18
Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer: AR-V7 is Rare in Hormone-sensitive Prostate Cancer. 62
36038450 2022
19
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. 62
36443902 2022
20
Correction to: Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. 62
36449389 2022
21
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. 62
36353661 2022
22
Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment. 62
36349511 2022
23
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. 62
36334968 2022
24
Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer. 62
36088181 2022
25
Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank. 62
35978138 2022
26
The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. 62
35301240 2022
27
The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. 62
36082555 2022
28
Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. 62
35411446 2022
29
Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes-ready for prime time? 62
36261588 2022
30
Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer: Imaging and Clinical Perspective in Prostate Cancer. 62
36229103 2022
31
Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. 62
36093578 2022
32
Re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. 62
35907665 2022
33
A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand. 62
36291883 2022
34
Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic Monitoring in Prostate Cancer Should Involve a Cotinine Test in Current Smokers: Smoking Cessation Remains a Cornerstone in Preventive Health Care Overall and for Men with Prostate Cancer. 62
35907663 2022
35
Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. 62
33483265 2022
36
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. 62
33249083 2022
37
Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. 62
34773473 2022
38
A Combinatorial Neural Network Analysis Reveals a Synergistic Behaviour of Multiparametric Magnetic Resonance and Prostate Health Index in the Identification of Clinically Significant Prostate Cancer. 62
35610113 2022
39
Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era? 62
36046616 2022
40
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. 62
35767071 2022
41
De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy. 62
35971165 2022
42
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. 62
32958451 2022
43
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. 62
34363009 2022
44
Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. 62
34334344 2022
45
Disparities in germline testing among racial minorities with prostate cancer. 62
34775478 2022
46
Racial disparities in prostate cancer among black men: epidemiology and outcomes. 62
34475523 2022
47
The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity. 62
35315585 2022
48
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. 62
34489536 2022
49
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. 62
34326474 2022
50
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. 62
34167925 2022

Variations for Prostate Cancer, Hereditary, 6

Expression for Prostate Cancer, Hereditary, 6

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 6.

Pathways for Prostate Cancer, Hereditary, 6

GO Terms for Prostate Cancer, Hereditary, 6

Sources for Prostate Cancer, Hereditary, 6

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....